Health Canada authorizes P-I clinical trial of Mod...
August 10, 2026
As the pharmaceutical industry becomes increasingly digital, cybersecurity is emerging as one of the sector’s most urgent and underestimated risks. Clinical trials, manufacturing operations, supply ch...
In-depth conversations with the executives, scientists, regulators, and innovators driving Canada’s pharmaceutical and life sciences landscape forward. Every policy decision, every drug approval...
For decades, oncology innovation has focused primarily on developing more effective treatments for advanced disease. Today, however, the industry is beginning to shift toward a new frontier: detecting...
Join thousands of pharmaceutical professionals, researchers, and healthcare leaders who rely on The Pharma Canada Newsletter for the most important industry updates, delivered straight to their inbox....
Original research, market analyses, and in-depth reports on the trends, policies, and pipelines shaping the future of pharmaceutical and life sciences in Canada. Canada’s pharmaceutical landscap...
Precision medicine is often defined by breakthrough therapies and targeted treatments, but behind many of these advances lies a less visible yet increasingly essential component: companion diagnostics...
The pharmaceutical industry has long occupied a complex position in public perception, celebrated for life saving innovation yet frequently criticized for pricing practices, transparency concerns, and...
The COVID-19 pandemic fundamentally transformed the global vaccine industry, accelerating scientific innovation, manufacturing investment, and public awareness at an unprecedented pace. Technologies t...
Rare diseases were once considered commercially unattractive due to their limited patient populations and high development costs. Today, however, they have become one of the fastest growing areas of i...
Sustainability in the pharmaceutical industry is evolving beyond environmental, social, and governance reporting into a broader strategic priority. What was once viewed primarily as a corporate respon...
